Active surveillance of the Japanese Encephalitis Inactivated Vaccine in children demonstrated an overall adverse event incidence rate of 111.34 per 10,000 doses, with no serious adverse reactions reported.
Observational
What is the incidence and safety profile of adverse events following immunization with the Japanese Encephalitis Inactivated Vaccine (JE-I) in children?
The Japanese Encephalitis Inactivated Vaccine demonstrated a favorable safety profile in children, with a low incidence of predominantly common adverse events and no serious adverse reactions.
OBJECTIVE: To evaluate the safety of the Japanese Encephalitis Inactivated Vaccine (JE-I) through an active surveillance in Jiangsu Province, China. RESEARCH DESIGN AND METHODS: Active follow-up was conducted among children vaccinated with JE-I from 1 January 2024, to 31 March 2025, and systematically document the occurrence of adverse events following immunization (AEFI). RESULTS: A total of 274 AEFI cases were identified, yielding an overall incidence rate of 111.34 per 10,000 doses. Incidence was significantly higher after the first dose than subsequent doses (χ2 = 315.849, CONCLUSION: JE-I AEFI incidence in Jiangsu was relatively low, predominantly common reactions. No serious adverse reactions were reported, indicating a favorable safety profile. CLINICAL TRIAL REGISTRATION: www.clinicaltrials.gov identifier is NCT06372665.
Li et al. (Tue,) conducted a observational in Japanese Encephalitis vaccination. Japanese Encephalitis Inactivated Vaccine (JE-I) was evaluated on Occurrence of adverse events following immunization (AEFI) per 10,000 doses. Active surveillance of the Japanese Encephalitis Inactivated Vaccine in children demonstrated an overall adverse event incidence rate of 111.34 per 10,000 doses, with no serious adverse reactions reported.